1530.HK - 3SBio Inc.

HKSE - HKSE Delayed Price. Currency in HKD
-0.44 (-2.38%)
At close: 4:08PM HKT
Stock chart is not supported by your current browser
Previous Close18.46
Bid18.00 x 0
Ask18.02 x 0
Day's Range17.56 - 18.80
52 Week Range9.45 - 23.25
Avg. Volume14,013,630
Market Cap45.749B
PE Ratio (TTM)40.62
EPS (TTM)0.44
Earnings DateN/A
Forward Dividend & Yield0.07 (0.38%)
Ex-Dividend Date2018-06-29
1y Target Est22.84
  • How Do Analysts See 3SBio Inc (HKG:1530) Performing In The Next Couple Of Years?
    Simply Wall St.27 days ago

    How Do Analysts See 3SBio Inc (HKG:1530) Performing In The Next Couple Of Years?

    3SBio Inc’s (HKG:1530) released its most recent earnings update in December 2017, which confirmed that the company gained from a strong tailwind, leading to a double-digit earnings growth of 31.27%.Read More...

  • Little Known China Biotech Firm Lures Top Global Stock Fund
    Bloomberg3 months ago

    Little Known China Biotech Firm Lures Top Global Stock Fund

    3SBio Inc., a Chinese biotech company that’s seen its revenue double in past two years, recently caught the eye of one of the world’s best performing global funds. Dynamic Power Global Growth Class -- the top performer among the 1,000 mutual funds investing globally in the past five years -- bought 17.4 million Hong Kong-listed shares of 3SBio a few months ago, making it the only Chinese healthcare stock in its $1.2 billion portfolio. “I’m always looking for companies where there is not only growth, but the ability to sustain that growth,” Noah Blackstein, the 48-old Canadian fund manager said in an interview last month when asked why Dynamic Power allocated about one third of its capital to Chinese stocks including 3SBio.

  • PR Newswire4 months ago

    3SBio Unveils 2017 Annual Results: Revenue Soars by 33.5%

    HONG KONG, March 26, 2018 /PRNewswire/ -- Leading Chinese biotechnology company 3SBio (01530.HK) today released its 2017 annual results, showing that the company has been dramatically growing with important progress made in all businesses. Looking to the future, the company intends to reinforce its position as a leading biopharmaceutical company in China by leveraging its integrated R&D, commercial, and manufacturing platforms. The company will also focus on developing leading biologics products that enable it to provide a variety of treatment options for patients.

  • Reuters6 months ago

    BRIEF-3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​


  • PR Newswire7 months ago

    China FDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Patients with Type-2 Diabetes

    SHANGHAI, Jan. 4, 2018 /PRNewswire/ -- 3Sbio Inc. (01530.HK) announced today that China's first Glucagon-like peptide-1 (GLP-1) receptor agonist weekly preparation Bydureon® (generic name Exenatide Microsphere for injection) has been formally approved by China Food and Drug Administration (CFDA), as a new treatment option to improve glycemic control for patients with type 2 diabetes. As the first and currently the only GLP-1 medicine in China to be administered once-weekly, exenatide microsphere can reduce the frequency of dosing, reduce gastrointestinal adverse effects and increase drug stability and improve patient compliance by continuing to provide steady-state levels of exenatide with sustained release microsphere technology, which will provide a new treatment option for the majority of patients with type 2 diabetes in China.

  • PR Newswire11 months ago

    3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure

    SHENYANG China, Sept. 3, 2017 /PRNewswire/ -- 3SBio Inc. (01530.HK, the "Group"), a leading Chinese biopharmaceutical company, is pleased to announce today that it has entered into a Shareholder Agreement with CPE Funds, pursuant to which a Joint Venture (the "JV") shall be established. The Group and CPE Funds seek to position the JV as a global, comprehensive and biologics-focused contract development and manufacturing (CDMO) platform. On September 1st, the JV entered into an Asset Purchase Agreement with Canada-based biologics manufacturer Therapure Biopharma Inc. to acquire its CDMO business, Therapure Biomanufacturing, for US$290 million.

  • 3SBio's Tan on Pipeline products, Opportunities, Regulation
    Bloomberg Video2 months ago

    3SBio's Tan on Pipeline products, Opportunities, Regulation

    May.29 -- Bo Tan, chief financial officer at 3SBio, discusses the opportunities he's seeing in China's red-hot healthcare sector, the products in the company pipeline, approvals and regulation changes, competition and acquisitions. He speaks exclusively on "Bloomberg Markets: Asia" from the Morgan Stanley China summit in Beijing.